Matching articles for "Ofloxacin"
Issue 1586 · December 2, 2019
Drugs for Common Eye Disorders

This issue includes reviews of drugs for glaucoma, age-related macular degeneration (AMD), bacterial conjunctivitis, and dry eye disease. Allergic conjunctivitis is reviewed in a separate issue.

Med Lett Drugs Ther. 2019 Dec 2; 61(1586):187-94
This issue includes reviews of drugs for glaucoma, age-related macular degeneration (AMD), bacterial conjunctivitis, and dry eye disease. Allergic conjunctivitis is reviewed in a separate issue.
Issue 1582 · October 7, 2019
Advice for Travelers

Patients who receive pretravel advice can reduce their risk for many travel-related conditions. Vaccines recommended for travelers are reviewed in a separate issue.

Med Lett Drugs Ther. 2019 Oct 7; 61(1582):153-60
Patients who receive pretravel advice can reduce their risk for many travel-related conditions. Vaccines recommended for travelers are reviewed in a separate issue.
Issue 1582 · October 7, 2019
Expanded Table: Antibiotics for Travelers' Diarrhea (online only)

View the Expanded Table: Antibiotics for Travelers' Diarrhea

Med Lett Drugs Ther. 2019 Oct 7; 61(1582):e160
View the Expanded Table: Antibiotics for Travelers' Diarrhea
Issue 1567 · March 11, 2019
Rifamycin (Aemcolo) for Treatment of Travelers' Diarrhea

The FDA has approved rifamycin ( Aemcolo – Cosmo/ Aries), a minimally absorbed oral antibiotic, for treatment of adults with travelers' diarrhea (TD) caused by noninvasive strains of Escherichia coli . It is…

Med Lett Drugs Ther. 2019 Mar 11; 61(1567):39-40
The FDA has approved rifamycin ( Aemcolo – Cosmo/ Aries), a minimally absorbed oral antibiotic, for treatment of adults with travelers' diarrhea (TD) caused by noninvasive strains of Escherichia coli . It is not recommended for treatment of diarrhea that is complicated by fever and/or bloody stools. Topical and injectable formulations of rifamycin have been used in Europe for other indications for many years.
Issue 1553 · August 13, 2018
Ciprofloxacin Otic Suspension (Otiprio) for Acute Otitis Externa

The FDA has approved a 6% otic suspension formulation of the fluoroquinolone antibiotic ciprofloxacin ( Otiprio – Otonomy) for single-dose treatment of acute otitis externa (swimmer's ear) caused by…

Med Lett Drugs Ther. 2018 Aug 13; 60(1553):135-6
The FDA has approved a 6% otic suspension formulation of the fluoroquinolone antibiotic ciprofloxacin ( Otiprio – Otonomy) for single-dose treatment of acute otitis externa (swimmer's ear) caused by Pseudomonas aeruginosa or Staphylococcus aureus in patients ≥6 months old. Otiprio was approved earlier for prophylaxis in children with bilateral otitis media with effusion who are undergoing tympanostomy tube placement.
Issue 1524 · July 3, 2017
Drugs for Sexually Transmitted Infections

The text and tables that follow include recommendations for management of sexually transmitted infections (STIs) other than HIV and viral hepatitis. Some of the indications and dosages recommended here have…

Med Lett Drugs Ther. 2017 Jul 3; 59(1524):105-12
The text and tables that follow include recommendations for management of sexually transmitted infections (STIs) other than HIV and viral hepatitis. Some of the indications and dosages recommended here have not been approved by the FDA.
Issue 1509 · December 5, 2016
Ciprofloxacin/Fluocinolone (Otovel) for Otitis Media with Tympanostomy Tubes

The FDA has approved Otovel (Arbor), a combination of the fluoroquinolone antibiotic ciprofloxacin 0.3% and the corticosteroid fluocinolone acetonide 0.025%, for otic treatment of acute otitis media with…

Med Lett Drugs Ther. 2016 Dec 5; 58(1509):153-5
The FDA has approved Otovel (Arbor), a combination of the fluoroquinolone antibiotic ciprofloxacin 0.3% and the corticosteroid fluocinolone acetonide 0.025%, for otic treatment of acute otitis media with tympanostomy tubes (AOMT) in children ≥6 months old. It is the second fluoroquinolone/corticosteroid combination to be approved for this indication; ciprofloxacin 0.3%/dexamethasone 0.1% (Ciprodex) has been available for many years. In December 2015, a suspension of ciprofloxacin 6% (Otiprio) was approved for otic treatment of bilateral otitis media with effusion in children undergoing tympanostomy tube placement.
Issue 1496 · June 6, 2016
Alternatives to Fluoroquinolones

The FDA has announced that it is requiring changes in the labeling of systemic fluoroquinolones to warn that the risk of serious adverse effects, including tendinitis, peripheral neuropathy and CNS effects,…

Med Lett Drugs Ther. 2016 Jun 6; 58(1496):75-6
The FDA has announced that it is requiring changes in the labeling of systemic fluoroquinolones to warn that the risk of serious adverse effects, including tendinitis, peripheral neuropathy and CNS effects, generally outweighs their benefit for the treatment of acute sinusitis, acute exacerbations of chronic bronchitis, and uncomplicated urinary tract infections. For these infections, the new labels will recommend reserving fluoroquinolones for patients with no other treatment options.
Issue 1495 · May 23, 2016
Ciprofloxacin (Otiprio) for Tympanostomy Tube Insertion

The FDA has approved ciprofloxacin 6% otic suspension ( Otiprio – Otonomy) for single-dose prophylaxis in children with bilateral otitis media with effusion who are undergoing tympanostomy tube placement. It…

Med Lett Drugs Ther. 2016 May 23; 58(1495):69-70
The FDA has approved ciprofloxacin 6% otic suspension ( Otiprio – Otonomy) for single-dose prophylaxis in children with bilateral otitis media with effusion who are undergoing tympanostomy tube placement. It is the first drug to be approved for this indication in the US. Otic formulations of the fluoroquinolone antibiotics ofloxacin ( Floxin Otic , and generics) and ciprofloxacin (plus dexamethasone; Ciprodex ) have been available for years for treatment of acute otitis media in children with tympanostomy tubes; an otic suspension containing ciprofloxacin and fluocinolone acetonide (Otovel) has recently been approved for the same indication and will be reviewed in a future issue.
Issue 1429 · November 11, 2013 Free
In Brief: Fluoroquinolones and Peripheral Neuropathy

The FDA is requiring new warnings about peripheral neuropathy in the labeling of all oral and injectable fluoroquinolones. The potential for this class of antibiotics to cause peripheral neuropathy was first…

Med Lett Drugs Ther. 2013 Nov 11; 55(1429):89
The FDA is requiring new warnings about peripheral neuropathy in the labeling of all oral and injectable fluoroquinolones. The potential for this class of antibiotics to cause peripheral neuropathy was first identified more than 10 years ago and a warning was added to their labels in 2004. The new warnings are based on a recent review of the FDA’s Adverse Event Reporting System (AERS) database. 1 The onset of peripheral neuropathy can occur rapidly, often within a few days of starting a fluoroquinolone, and in some patients the disorder may be permanent. Symptoms include pain, tingling, burning, numbness, weakness, and change in sensation to touch, pain, and temperature in the arms and/or legs. If peripheral neuropathy develops in a patient taking a fluoroquinolone, the drug should be stopped and an antibacterial from a different class should be used instead. 2 1. FDA Drug Safety Communication: FDA requires label changes to warn of risk for possibly permanent nerve damage from antibacterial fluoroquinolone drugs taken by mouth or by injection. Available at http://www.fda.gov. Accessed November 1, 2013. 2. Drugs for bacterial infections. Treat Guidel Med Lett 2013; 11:65. Download complete U.S. English article
Issue 131 · July 1, 2013
Drugs for Bacterial Infections

The text that follows reviews some common bacterial infections and their empiric treatment pending the results of culture and susceptibility testing. The recommendations made here are based on the results of…

Treat Guidel Med Lett. 2013 Jul; 11(131):65-74
The text that follows reviews some common bacterial infections and their empiric treatment pending the results of culture and susceptibility testing. The recommendations made here are based on the results of susceptibility studies, clinical trials, and the opinions of Medical Letter reviewers. Tables 1 and 2 list the usual dosages of antibacterial drugs.
Issue 123 · November 1, 2012
Drugs for Some Common Eye Disorders

Drugs for glaucoma, age-related macular degeneration, bacterial conjunctivitis, and dry eyes are reviewed here. Drugs for the treatment of allergic conjunctivitis will be reviewed in a future issue of…

Treat Guidel Med Lett. 2012 Nov; 10(123):79-86
Drugs for glaucoma, age-related macular degeneration, bacterial conjunctivitis, and dry eyes are reviewed here. Drugs for the treatment of allergic conjunctivitis will be reviewed in a future issue of Treatment Guidelines on Drugs for Allergic Disorders.
Issue 122 · October 1, 2012
Antimicrobial Prophylaxis for Surgery

Antimicrobial prophylaxis can decrease the incidence of postoperative infection, particularly surgical site infection, after some procedures. Recommendations for such prophylaxis are listed in the table that…

Treat Guidel Med Lett. 2012 Oct; 10(122):73-8
Antimicrobial prophylaxis can decrease the incidence of postoperative infection, particularly surgical site infection, after some procedures. Recommendations for such prophylaxis are listed in the table that begins on page 74. Antimicrobial prophylaxis for dental procedures to prevent endocarditis was recently discussed in The Medical Letter .
Issue 118 · June 1, 2012
Advice for Travelers

Patients planning to travel to other countries often ask for information about appropriate vaccines and prevention of diarrhea and malaria. More detailed advice for travelers is available from the Centers for…

Treat Guidel Med Lett. 2012 Jun; 10(118):45-56
Patients planning to travel to other countries often ask for information about appropriate vaccines and prevention of diarrhea and malaria. More detailed advice for travelers is available from the Centers for Disease Control and Prevention (CDC) at www.cdc.gov/travel. Guidelines are also available from the Infectious Diseases Society of America (IDSA).
Issue 1368 · July 11, 2011
Levofloxacin Revisited

A Medical Letter reader has asked us to review the safety of the fluoroquinolone antibiotic levofloxacin ( Levaquin – Ortho-McNeil-Janssen), which has just been approved for generic use by the FDA and has…

Med Lett Drugs Ther. 2011 Jul 11; 53(1368):55-6
A Medical Letter reader has asked us to review the safety of the fluoroquinolone antibiotic levofloxacin ( Levaquin – Ortho-McNeil-Janssen), which has just been approved for generic use by the FDA and has been at the center of some recent lawsuits regarding the adequacy of its safety warnings.
Issue 95 · July 1, 2010
Drugs for Sexually Transmitted Infections

Many infections can be transmitted during sexual contact. The text and tables that follow are limited to management of sexually transmitted infections (STIs) other than HIV, viral hepatitis and enteric…

Treat Guidel Med Lett. 2010 Jul; 8(95):53-60
Many infections can be transmitted during sexual contact. The text and tables that follow are limited to management of sexually transmitted infections (STIs) other than HIV, viral hepatitis and enteric infections. The drugs of choice, their dosages and alternatives are listed in a table that begins on page 54. A table listing the adverse effects of some of these antimicrobials begins on page 58.
Issue 94 · June 1, 2010
Drugs for Bacterial Infections

The text below reviews some common bacterial infections and their treatment. The recommendations made here are based on the results of susceptibility studies, clinical trials and the opinions of Medical Letter…

Treat Guidel Med Lett. 2010 Jun; 8(94):43-52
The text below reviews some common bacterial infections and their treatment. The recommendations made here are based on the results of susceptibility studies, clinical trials and the opinions of Medical Letter consultants.
Issue 89 · January 1, 2010
Drugs for Some Common Eye Disorders

Drugs for glaucoma, age-related macular degeneration, bacterial conjunctivitis, and dry eyes are reviewed here. Ophthalmic drugs can have local and systemic adverse effects. In addition, for some elderly…

Treat Guidel Med Lett. 2010 Jan; 8(89):1-8
Drugs for glaucoma, age-related macular degeneration, bacterial conjunctivitis, and dry eyes are reviewed here. Ophthalmic drugs can have local and systemic adverse effects. In addition, for some elderly patients, the complexity of self-administering numerous ophthalmic drugs may be the limiting factor in their ability to care for themselves. Drugs for the treatment of allergic conjunctivitis will be reviewed in a future issue of Treatment Guidelines on Drugs for Allergic Disorders.
Issue 1327 · December 14, 2009
Ophthalmic Besifloxacin (Besivance)

The FDA has approved the fluoroquinolone besifloxacin 0.6% ophthalmic suspension ( Besivance - Bausch & Lomb) for treatment of bacterial conjunctivitis caused by susceptible bacteria. According to the…

Med Lett Drugs Ther. 2009 Dec 14; 51(1327):101-3
The FDA has approved the fluoroquinolone besifloxacin 0.6% ophthalmic suspension ( Besivance - Bausch & Lomb) for treatment of bacterial conjunctivitis caused by susceptible bacteria. According to the manufacturer, this product was developed specifically for ophthalmic use in a specialized vehicle designed to prolong contact time on the ocular surface. Besifloxacin is not available for systemic use.
Issue 87 · November 1, 2009
Advice for Travelers

Patients planning to travel to other countries often ask physicians for information about appropriate vaccines and prevention of diarrhea and malaria. Guidelines are also available from the Infectious Diseases…

Treat Guidel Med Lett. 2009 Nov; 7(87):83-94
Patients planning to travel to other countries often ask physicians for information about appropriate vaccines and prevention of diarrhea and malaria. Guidelines are also available from the Infectious Diseases Society of America (IDSA).
Issue 82 · June 1, 2009
Antimicrobial Prophylaxis for Surgery

Antimicrobial prophylaxis can decrease the incidence of infection, particularly surgical site infection, after certain procedures. Recommendations for prevention of surgical site infection are listed in the…

Treat Guidel Med Lett. 2009 Jun; 7(82):47-52
Antimicrobial prophylaxis can decrease the incidence of infection, particularly surgical site infection, after certain procedures. Recommendations for prevention of surgical site infection are listed in the table that begins on page 48. Antimicrobial prophylaxis for dental procedures to prevent endocarditis is discussed in The Medical Letter 2007; 49:99 .
Issue 1300 · December 1, 2008 Free
In Brief: Fluoroquinolones and Tendon Injuries

The FDA has added a boxed warning to fluoroquinolone package inserts about tendon injuries that may occur as a result of their use. Tendinitis or tendon rupture may occur rarely with systemic use of any…

Med Lett Drugs Ther. 2008 Dec 1; 50(1300):93
The FDA has added a boxed warning to fluoroquinolone package inserts about tendon injuries that may occur as a result of their use. Tendinitis or tendon rupture may occur rarely with systemic use of any fluoroquinolone, either while the drug is being taken or for up to several months afterwards. Fluoroquinolone-related tendon injury is rare; estimates for its incidence in the general population range from 0.14% to 0.4%. The risk is higher for patients >60 years old and for those taking corticosteroids. For patients with organ transplants, the incidence may be as high as 15%. 1 A case-control study in Italy involving 22,194 cases of non-traumatic tendinitis and 104,906 controls found that fluoroquinolone use was significantly associated with tendon disorders in general (OR 1.7; 95% CI 1.4-2.0), tendon rupture (OR 1.3; 95% CI 1.0-1.8), and Achilles tendon rupture (OR 4.1; 95% CI 1.8-9.6). Achilles tendon rupture occurred with fluoroquinolone treatment in one of every 5989 patients in general and in one of every 1638 patients >60 years old. 2 Widespread use of fluoroquinolones, particularly for treatment of respiratory infections, has produced substantial bacterial resistance to this class of drugs and has been associated with an increase in the incidence and severity of Clostridium difficile disease. 3 Even when bacterial pneumonia is considered a likely possibility, other drugs are generally preferred, at least in non-elderly, otherwise healthy patients. 4 1. F Muzi et al. Fluoroquinolones-induced tendinitis and tendon rupture in kidney transplant recipients: 2 cases and a review of the literature.Transplant Proc 2007; 39:1673. 2. G Corrao et al. Evidence of tendinitis provoked by fluoroquinolone treatment: a case-control study. Drug Saf 2006; 29:889. 3. Treatment of Clostridium difficile-associated disease (CDAD). Med Lett Drugs Ther 2006; 48:89. 4. Drugs for community-acquired bacterial pneumonia. Med Lett Drugs Ther 2007; 49:62. Download: U.S. English
Issue 1291 · July 28, 2008
Drugs for Travelers' Diarrhea

The most common cause of travelers' diarrhea, usually a self-limited illness without fever lasting several days, is infection with noninvasive enterotoxigenic (ETEC) or enteroaggregative (EAEC) strains of…

Med Lett Drugs Ther. 2008 Jul 28; 50(1291):58-9
The most common cause of travelers' diarrhea, usually a self-limited illness without fever lasting several days, is infection with noninvasive enterotoxigenic (ETEC) or enteroaggregative (EAEC) strains of Escherichia coli. Campylobacter, Shigella, Salmonella, Aeromonas, viruses and parasites are less common.
Issue 61 · September 1, 2007
Drugs for Sexually Transmitted Infections

Many infections can be transmitted during sexual contact. The text and tables that follow are limited to management of sexually transmitted infections (STIs) other than HIV, viral hepatitis and enteric…

Treat Guidel Med Lett. 2007 Sep; 5(61):81-9
Many infections can be transmitted during sexual contact. The text and tables that follow are limited to management of sexually transmitted infections (STIs) other than HIV, viral hepatitis and enteric infections. Guidelines are available from the US Centers for Disease Control and Prevention (CDC) with detailed recommendations for treatment of these diseases.
Issue 57 · May 1, 2007
Choice of Antibacterial Drugs

Information about empirical treatment of bacterial infections, emerging trends in antimicrobial resistance, new drugs and new data about older drugs continue to become available. Usual pathogens and empiric…

Treat Guidel Med Lett. 2007 May; 5(57):33-50
Information about empirical treatment of bacterial infections, emerging trends in antimicrobial resistance, new drugs and new data about older drugs continue to become available. Usual pathogens and empiric treatment for some common types of infections are summarized in the text and a table listing the drugs of choice and alternatives for each pathogen begins on page 40. The recommendations made here are based on the results of susceptibility studies, clinical trials and the opinions of Medical Letter consultants.
Issue 52 · December 1, 2006
Antimicrobial Prophylaxis for Surgery

Antimicrobial prophylaxis can decrease the incidence of infection, particularly surgical site infection, after certain procedures. Recommendations for prevention of surgical site infection are listed in this…

Treat Guidel Med Lett. 2006 Dec; 4(52):83-8
Antimicrobial prophylaxis can decrease the incidence of infection, particularly surgical site infection, after certain procedures. Recommendations for prevention of surgical site infection are listed in this article.
Issue 28 · December 1, 2004
Drugs for Tuberculosis

Tuberculosis (TB) is still a problem in the United States, even though the incidence continues to decline in most of the country (MMWR Morbid Mortal Wkly Rep 2004; 53:209). Treatment of TB can be divided into…

Treat Guidel Med Lett. 2004 Dec; 2(28):83-2
Tuberculosis (TB) is still a problem in the United States, even though the incidence continues to decline in most of the country (MMWR Morbid Mortal Wkly Rep 2004; 53:209). Treatment of TB can be divided into treatment of latent infection diagnosed by a positive PPD and treatment of active clinical TB. Guidelines with detailed management recommendations are available from the US Centers for Disease Control and Prevention (CDC) (MMWR Morbid Mortal Wkly Rep 2003; 52RR-11:1).
Issue 26 · October 1, 2004
Drugs for Sexually Transmitted Infections

Many infections can be transmitted during sexual contact. The text and tables that follow are limited to management of sexually transmitted infections (STIs) other than HIV, viral hepatitis and enteric…

Treat Guidel Med Lett. 2004 Oct; 2(26):67-74
Many infections can be transmitted during sexual contact. The text and tables that follow are limited to management of sexually transmitted infections (STIs) other than HIV, viral hepatitis and enteric infections. Guidelines are available from the US Centers for Disease Control and Prevention (CDC) with detailed recommendations for treatment of these diseases (MMWR Recomm Rep 2002; 51, RR-6:1). New guidelines are expected soon.
Issue 1191 · September 13, 2004
Rifaximin (Xifaxan) for Travelers' Diarrhea

Rifaximin ( Xifaxan - Salix), a non-absorbed oral antibiotic derived from rifampin ( Rifadin , and others), has been approved by the FDA for treatment of travelers' diarrhea caused by noninvasive strains of…

Med Lett Drugs Ther. 2004 Sep 13; 46(1191):74-5
Rifaximin ( Xifaxan - Salix), a non-absorbed oral antibiotic derived from rifampin ( Rifadin , and others), has been approved by the FDA for treatment of travelers' diarrhea caused by noninvasive strains of Escherichia coli in patients 12 years of age or older. It has been available in Europe since 1987.
Issue 21 · May 1, 2004
Advice for Travelers

Patients planning to travel to other countries often ask physicians for advice about immunizations and prevention of diarrhea and malaria. More detailed advice for travelers is available from the Centers for…

Treat Guidel Med Lett. 2004 May; 2(21):33-40
Patients planning to travel to other countries often ask physicians for advice about immunizations and prevention of diarrhea and malaria. More detailed advice for travelers is available from the Centers for Disease Control (CDC) at 877-FYI-TRIP (877-394-8747) or www.cdc.gov/travel . Recommendations for the treatment of parasitic diseases are available in the public reading room of The Medical Letter's web site.
Issue 20 · April 1, 2004
Antimicrobial Prophylaxis for Surgery

Antimicrobial prophylaxis can decrease the incidence of infection, particularly surgical site infection, after certain operations, but this benefit must be weighed against the risks of toxic and allergic…

Treat Guidel Med Lett. 2004 Apr; 2(20):27-32
Antimicrobial prophylaxis can decrease the incidence of infection, particularly surgical site infection, after certain operations, but this benefit must be weighed against the risks of toxic and allergic reactions, emergence of resistant bacteria, adverse drug interactions, superinfection and cost. Medical Letter consultants generally recommend antimicrobial prophylaxis only for procedures with high infection rates, those involving implantation of prosthetic material, and those in which the consequences of infection are likely to be especially serious.
Issue 1179 · March 29, 2004
Ophthalmic Moxifloxacin (Vigamox) and Gatifloxacin (Zymar)

Two new fluoroquinolone solutions, moxifloxacin 0.5% ( Vigamox - Alcon) and gatifloxacin 0.3% ( Zymar - Allergan) are now available in the US for ophthalmic use in treatment of bacterial conjunctivitis.

Med Lett Drugs Ther. 2004 Mar 29; 46(1179):25-7
Two new fluoroquinolone solutions, moxifloxacin 0.5% ( Vigamox - Alcon) and gatifloxacin 0.3% ( Zymar - Allergan) are now available in the US for ophthalmic use in treatment of bacterial conjunctivitis.
Issue 19 · March 1, 2004
Choice of Antibacterial Drugs

New drugs for bacterial infections and new information about older drugs continue to become available. Empirical treatment of some common bacterial infections is discussed in this article. A table listing the…

Treat Guidel Med Lett. 2004 Mar; 2(19):13-22
New drugs for bacterial infections and new information about older drugs continue to become available. Empirical treatment of some common bacterial infections is discussed in this article. A table listing the drugs of choice and alternatives for each pathogen begins on page 18. These recommendations are based on results of susceptibility studies, clinical trials and the opinions of Medical Letter consultants. Local resistance patterns should be taken into account. Trade names are listed on page 24.
Issue 1159 · June 23, 2003
Prilosec, Nexium and Stereoisomers

Recently pharmaceutical manufacturers have marketed a stereoisomer of a successful drug nearing patent expiration as a new drug. Examples, such as esomeprazole (Nexium) , levalbuterol (Xopenex), escitalopram…

Med Lett Drugs Ther. 2003 Jun 23; 45(1159):51-2
Recently pharmaceutical manufacturers have marketed a stereoisomer of a successful drug nearing patent expiration as a new drug. Examples, such as esomeprazole (Nexium) , levalbuterol (Xopenex), escitalopram (Lexapro) and dexmethylphenidate
Issue 1128 · April 15, 2002
Advice for Travelers

Patients planning to travel to other countries often ask physicians for advice about immunizations and prevention of diarrhea and malaria. More detailed advice for travelers is available from the CDC at…

Med Lett Drugs Ther. 2002 Apr 15; 44(1128):33-8
Patients planning to travel to other countries often ask physicians for advice about immunizations and prevention of diarrhea and malaria. More detailed advice for travelers is available from the CDC at 877-FYI-TRIP (877-394-8747) or www.cdc.gov/travel .
Issue 1116 · October 29, 2001
Post-exposure Anthrax Prophylaxis

Superseded by Handbook of Antimicrobial Therapy The Medical Letter article on Drugs and Vaccines against Biological Weapons, published in the previous issue (October 15, 2001, page 87), included a brief…

Med Lett Drugs Ther. 2001 Oct 29; 43(1116):91-2
Superseded by Handbook of Antimicrobial Therapy The Medical Letter article on Drugs and Vaccines against Biological Weapons, published in the previous issue (October 15, 2001, page 87), included a brief discussion of post-exposure prophylaxis of inhalation anthrax. Recent events call for more detail.
Issue 1062 · September 24, 1999
Drugs for Sexually Transmitted Infections

Many infections can be transmitted during sexual contact. The text and tables [in this article] are limited to treatment of non-HIV infections associated primarily with sexual transmission.

Med Lett Drugs Ther. 1999 Sep 24; 41(1062):85-90
Many infections can be transmitted during sexual contact. The text and tables [in this article] are limited to treatment of non-HIV infections associated primarily with sexual transmission.
Issue 1051 · April 23, 1999
Advice for Travelers

Patients planning to travel to other countries often ask pysicians for advice about immunizations and prevention of diarrhea and malaria. Legal requirements for entry and epidemiological conditions in…

Med Lett Drugs Ther. 1999 Apr 23; 41(1051):39-42
Patients planning to travel to other countries often ask pysicians for advice about immunizations and prevention of diarrhea and malaria. Legal requirements for entry and epidemiological conditions in different countries vary from time to time, often unpredictably, but some reasonable recommendations can be made.
Issue 1022 · March 13, 1998
Trovafloxacin

Trovafloxacin ( Trovan - Pfizer) and its prodrug alatrofoxacin (Trovan IV) are new fluroroquinolones marketed for an unusually wide variety of infections, including oral and intravenous treatment of nosocomial…

Med Lett Drugs Ther. 1998 Mar 13; 40(1022):30-1
Trovafloxacin ( Trovan - Pfizer) and its prodrug alatrofoxacin (Trovan IV) are new fluroroquinolones marketed for an unusually wide variety of infections, including oral and intravenous treatment of nosocomial and community-acquired pneumonia, acute ecerbations of chronic bronchitis, acute sinusitis, complicate intra-abdominal and pelvic infections, diabetic foot infection, uncomplicated urinary tract infection, prostatitis, cervicitis and uncomplicated gonorrhea.
Issue 1019 · January 30, 1998
Grepafloxacin--A New Fluoroquinolone

Grepafloxacin ( Raxar - Glaxo Wellcome), a once-daily oral fluoroquinolone, is now being marketed for treatment of community-acquired pneumonia, acute bacterial exacerbations of chronic bronchitis,…

Med Lett Drugs Ther. 1998 Jan 30; 40(1019):17-8
Grepafloxacin ( Raxar - Glaxo Wellcome), a once-daily oral fluoroquinolone, is now being marketed for treatment of community-acquired pneumonia, acute bacterial exacerbations of chronic bronchitis, uncomplicated gonorrhea, and nongonococcal urethritis and cervicitis.
Issue 1005 · July 18, 1997
Fosfomycin for Urinary Tract Infections

Fosfomycin, a broad-spectrum antibiotic used parenterally in Europe for many years, has been approved by the US Food and Drug Administration (FDA) as fosfomycin tromethamine ( Monurol - Forest) for single-dose…

Med Lett Drugs Ther. 1997 Jul 18; 39(1005):66-8
Fosfomycin, a broad-spectrum antibiotic used parenterally in Europe for many years, has been approved by the US Food and Drug Administration (FDA) as fosfomycin tromethamine ( Monurol - Forest) for single-dose oral treatment of uncomplicated urinary tract infections in women.
Issue 999 · April 25, 1997
Sparfloxacin and Levofloxacin

Sparfloxacin ( Zagam - Rh ne-Poulenc Rorer) and levofloxacin ( Levaquin - Ortho-McNeil) are the newest fluoroquinolone antimicrobials to be approved by the US Food and Drug Administration. Sparfloxacin in a…

Med Lett Drugs Ther. 1997 Apr 25; 39(999):41-3
Sparfloxacin ( Zagam - Rh ne-Poulenc Rorer) and levofloxacin ( Levaquin - Ortho-McNeil) are the newest fluoroquinolone antimicrobials to be approved by the US Food and Drug Administration. Sparfloxacin in a once-daily oral preparation is being marketed for treatment of community-acquired pneumonia and acute bacterial exacerbations of chronic bronchitis. Levofloxacin, which is the active stereoisomer of ofloxacin ( Floxin ), is available for either oral or parenteral use; it is approved for oncedaily treatment of community-acquired pneumonia, acute exacerbations of chronic bronchitis, sinusitis, skin and skin structure infections and complicated urinary tract infections.
Issue 969 · March 1, 1996
Advice For Travelers

Patients planning to travel to other countries often ask physicians for advice about immunizations and prevention of diarrhea and malaria. More detailed advice for travelers is available from the CDC at…

Med Lett Drugs Ther. 1996 Mar 1; 38(969):17-20
Patients planning to travel to other countries often ask physicians for advice about immunizations and prevention of diarrhea and malaria. More detailed advice for travelers is available from the CDC at 877-FYI-TRIP (877-394-8747) or www.cdc.gov/travel.
Issue 954 · August 4, 1995
Drugs For Tuberculosis

Tuberculosis (TB) continues to be a major problem in the United States, particularly in areas where drug resistance is common (Morbid Mortal Weekly Rep, 44:387, May 26, 1995). Since poor compliance is the most…

Med Lett Drugs Ther. 1995 Aug 4; 37(954):67-70
Tuberculosis (TB) continues to be a major problem in the United States, particularly in areas where drug resistance is common (Morbid Mortal Weekly Rep, 44:387, May 26, 1995). Since poor compliance is the most important cause of treatment failure and is associated with emergence of drug resistence, some experts now recommend that all patients take drugs for TB under direct observation (SE Weis et al, N Engl J Med, 330:1179, 1994; R Bayer and D Wilkinson, Lancet, 345:1545, June 17, 1995).
Issue 922 · May 13, 1994
Advice For Travelers
Med Lett Drugs Ther. 1994 May 13; 36(922):41-4
Issue 908 · October 29, 1993
Drugs for Tuberculosis

The rising incidence of tuberculosis (TB) has been accompanied by a dramatic increase in drug resistance in some areas of the USA (TR Frieden et al, N Engl J Med, 328:521, 1993). Since poor compliance is the…

Med Lett Drugs Ther. 1993 Oct 29; 35(908):99-102
The rising incidence of tuberculosis (TB) has been accompanied by a dramatic increase in drug resistance in some areas of the USA (TR Frieden et al, N Engl J Med, 328:521, 1993). Since poor compliance is the most important cause of treatment failure and associated with emergence of drug resistance, some experts now recommend that patients with TB take their drugs under direct obeservation (MD Iseman et al, N Engl J Med, 329:576, 1993).
Issue 884 · November 27, 1992
Cefpodoxime Proxetil - A New Oral Cephalosporin

Cefpodoxime proxetil ( Vantin - Upjohn), a new third-generation oral cephalosporin, has been approved for marketing by the US Food and Drug Administration. It is available for twice-daily treatment of…

Med Lett Drugs Ther. 1992 Nov 27; 34(884):107-8
Cefpodoxime proxetil ( Vantin - Upjohn), a new third-generation oral cephalosporin, has been approved for marketing by the US Food and Drug Administration. It is available for twice-daily treatment of pharyngitis, upper and lower respiratory infections, otitis media, urinary tract infections, skin and soft tissue infections, and for single-dose treatment of uncomplicated gonorrhea in men or women and anorectal gonorrhea in women.
Issue 883 · November 13, 1992
Enoxacin - A New Fluoroquinolone

Enoxacin (en ox' a sin; Penetrex - Rh ne-Poulenc Rorer), a fluoroquinolone antimicrobial for oral use, has now been marketed in the USA for treatment of urinary tract infections and uncomplicated urethral or…

Med Lett Drugs Ther. 1992 Nov 13; 34(883):103-5
Enoxacin (en ox' a sin; Penetrex - Rh ne-Poulenc Rorer), a fluoroquinolone antimicrobial for oral use, has now been marketed in the USA for treatment of urinary tract infections and uncomplicated urethral or cervical gonorrhea.
Issue 872 · June 12, 1992
Two New Fluoroquinolones

Temafloxacin ( Omniflox - Abbott) and lomefloxacin ( Maxaquin - Searle) are the latest fluoroquinolone antimicrobial agents to be approved by the US Food and Drug Administration (FDA) for oral treatment of…

Med Lett Drugs Ther. 1992 Jun 12; 34(872):58-60
Temafloxacin ( Omniflox - Abbott) and lomefloxacin ( Maxaquin - Searle) are the latest fluoroquinolone antimicrobial agents to be approved by the US Food and Drug Administration (FDA) for oral treatment of various infections. Previously marketed include norfloxacin ( Noroxin - Medical Letter, 29:25, 1987), ciprofloxacin ( Cipro - Medical Letter, 30:11, 1988), and ofloxacin ( Floxin - Medical Letter, 33:71, 1991). Norfloxacin is marketed only for treatment of urinary tract infections, and lomefloxacin only for treatment of urinary tract infections and bronchitis known to be caused by Haemophilus influenzae or Moraxella catarrhalis . Ciprofloxacin and ofloxacin are also available in parenteral formulations.
Issue 863 · February 7, 1992
Drugs for Tuberculosis

After many years of decline in the USA, the incidence of tuberculosis (TB) has recently increased, partly because the disease occurs more frequently in patients with human immunodeficiency virus (HIV)…

Med Lett Drugs Ther. 1992 Feb 7; 34(863):10-2
After many years of decline in the USA, the incidence of tuberculosis (TB) has recently increased, partly because the disease occurs more frequently in patients with human immunodeficiency virus (HIV) infection and in the homeless (PF Barnes et al, N Engl J Med, 324:1644, 1991; Morbid Mortal Weekly Rep, 40:869, Dec 20, 1991).
Issue 849 · July 26, 1991
Ofloxacin

Ofloxacin ( Floxin - McNeil, Ortho), a new fluoroquinolone antibacterial agent, was recently marketed in the USA for oral treatment of various infections caused by susceptible microorganisms. Ofloxacin is the…

Med Lett Drugs Ther. 1991 Jul 26; 33(849):71-3
Ofloxacin ( Floxin - McNeil, Ortho), a new fluoroquinolone antibacterial agent, was recently marketed in the USA for oral treatment of various infections caused by susceptible microorganisms. Ofloxacin is the third fluoroquinolone to become available in this country. Norfloxacin ( Noroxin - Medical Letter, 29:25, 1987) is marketed only for treatment of urinary tract infections. Ciprofloxacin ( Cipro - Medical Letter, 30:11, 1988), like ofloxacin, is approved for use in a variety of infections.